Qualified Person Training: EU GMP Annex 16 Batch Certification

Opens with the question of whose signature a batch must carry before sale in the EU. Then two cases. In October 2023, EMA reported falsified pens labelled as Ozempic at EU and UK wholesalers, exposed when their copied serial numbers showed as inactive, and why the QP must make sure safety features such as the unique identifier are on every pack. Then EMA's December 2019 report of trace NDMA in some metformin medicines outside the EU, and why the QP must know the supply chain. Explains that the QP answers for each batch while the marketing authorisation holder answers for the product over its lifetime. Introduces JKL Pharma Europe in Dublin, the EU authorisation holder and importer for batches made in Mumbai and Singapore and tested in Dublin. Outlines the twelve modules, four exercises and exam, and closes with a recap.

What you will be able to do

• Explain what a Qualified Person certifies before EU release
• Describe how pack safety features protect against falsified medicines
• Tell the QP's batch responsibility from the holder's lifetime responsibility

Why it matters

No batch reaches EU patients without a QP's decision; knowing the role shows what every site in the chain must provide.

Practice: Practice: Welcome: the last signature · 3 questions

Starts with how JKL Pharma Europe got permission to import its first batch: an application to the Irish authority, prepared premises with quarantine areas and a laboratory, a named QP and an inspection, then a manufacturing and importation authorisation. Reads Article 40 of Directive 2001/83/EC, including paragraph 3 on imports from third countries, and why an importer needs an MIA. Covers Article 48, requiring at least one QP permanently and continuously available, and Article 51 on the QP's duties: each batch made and checked as required, imports tested in the EU, safety features and a register. Shows the Dublin QP's control report travelling with MET500 to Germany, and point 1.1 at a Frankfurt contract manufacturer whose QP confirms steps but may not certify. Explains Annex 16, in operation since April 2016, which never overrides the marketing authorisation, the evidence an inspector asks for, and a recap.

What you will be able to do

• Explain why an EU importer needs a manufacturing and importation authorisation
• Describe the QP duties set out in Article 51
• Explain how Annex 16 relates to EU law and the marketing authorisation

Why it matters

The QP's role is set by law and made possible by the holder; knowing the legal basis shows what the company must provide.

Practice: Practice: The Qualified Person in EU law · 3 questions

Opens with a built example: a quality assurance manager at JKL Pharma Europe with fifteen years in the industry and a chemistry degree asks to become the deputy QP. Explains why seniority is not the test, and reads Article 49's two conditions: a university qualification in a listed scientific discipline, and at least two years of practical experience at authorised manufacturers. Lists the basic subjects, from pharmacy and pharmaceutical chemistry to toxicology, and checks her eligibility, including three years in quality control at a Dublin manufacturer. Covers a typical route to becoming a QP, Annex 16's expectation of detailed knowledge of every step, continuous training, and the QP reviewing the Mumbai process every two years. Explains the QP's position, where no one can overrule her decision on a batch, and the contract packager's own QP in Frankfurt. Ends with good practice, a common mistake and a recap.

What you will be able to do

• Check a candidate against the Article 49 qualification conditions
• Explain the practical experience a Qualified Person needs
• Plan continuous training that covers every step the QP certifies

Why it matters

Experience alone does not qualify a QP; knowing the conditions avoids appointing someone the authority will not accept.

Practice: Practice: Who may act as a Qualified Person · 3 questions

Follows MET500 batch 2431 from Mumbai to saleable stock in the EU: made, tested and packed in Mumbai, shipped under quarantine, tested in Dublin, certified by the QP and then moved to saleable stock. Asks which moment is the release, and reads Annex 16's three steps: checking manufacture and testing, certification by a QP as the quality release, and transfer to saleable stock or export. Explains certification of the finished batch in its final pack, by a QP named in the marketing authorisation, recorded in a register, and why for imports importation and certification are the last stages of manufacture, with transport conditions part of the decision. Shows JKL's register entry for batch 2431 and what reviewers check. Covers an importer in Frankfurt, a warehouse system that will not move stock without the QP's electronic notice,. Closes with a recap: the date never decides, the QP does.

What you will be able to do

• Describe the three steps of batch release in the right order
• Explain what QP certification means and how it is recorded
• Check that stock cannot move to saleable before certification

Why it matters

Commercial pressure tempts shortcuts in release; knowing the three steps and their owners keeps them in order.

Practice: Practice: The three steps of batch release · 3 questions

Starts with a built example: MET500 for Germany is made and blister packed in Mumbai, tested in Dublin, packed into German cartons by a contract packager in Frankfurt and certified by the Dublin QP. Asks how she knows each site did its part. Reads point 1.4 on a QP at each EU site, point 1.4.1 on confirmations by QPs at sites doing part of the work, and how the certifying QP takes full responsibility or shares it formally. Explains a confirmation as a signed, specific statement with the content set out in Appendix I, and why an email text alone does not count at JKL. Shows part of the responsibility table between JKL Pharma Europe and the Frankfurt packager under point 1.4.3 and a yearly mock recall. Ends with deviations copied to the Dublin QP the day they are raised, a practice exercise and a recap.

What you will be able to do

• Explain what a QP confirmation must contain under Appendix I
• Set out shared responsibilities between QPs in a written agreement
• Make sure deviations at partner sites reach the certifying QP

Why it matters

When several sites touch one batch, responsibilities not written down before are argued about after something goes wrong.

Practice: Practice: Multi-site manufacture and confirmations · 3 questions

Opens with a built example: ceftriaxone batch 5107 from JKL's Singapore site, fully tested there, tested again in Dublin before the QP reviews both sets of results. Explains why EU law sees this as a safeguard. Reads point 1.5.4: unless a mutual recognition agreement or similar applies, each imported batch is tested in a Member State, with a full qualitative analysis, the actives quantified and all other necessary tests. Shows JKL's EU test plan, what happens when a batch arrives, and a contract laboratory in the EU for a test Dublin cannot do. Explains that mutual recognition agreements may relieve the QP of testing, but never of certifying, and that each has its own scope, with an importer bringing in tablets from Boston. Covers JKL's scope check naming the exact site address, the QP's control report going with each batch, good practice, a costly mistake and a recap.

What you will be able to do

• Explain what EU testing of an imported batch must include
• Check whether a mutual recognition agreement covers a product and site
• Prepare a control report that travels with each certified batch

Why it matters

Assuming an agreement applies can lead to batches certified without required EU testing; checking scope avoids that.

Practice: Practice: Importation, EU testing and mutual recognition · 3 questions

Starts with a proposal at JKL Pharma Europe to take EU test samples of MET500 in Mumbai and fly them to Dublin while the batch is still at sea, saving weeks. Reads point 1.5.5's four rules: fully representative sampling, a technically justified approach for third-country sampling, responsibilities in a written agreement, and samples shipped under conditions equivalent to the batch. Shows how JKL plans the scientific study for MET500, investigates packing and container conditions when results differ, and writes its agreement, with trained Mumbai staff following JKL's sampling plan. Covers the audit, periodic checks after import and review of unexpected results, then batches from one bulk under point 1.5.7, with five verifications each, at an importer in Paris. Explains what an inspector would expect, the mistake point 1.5.6 prevents, quarterly reviews, a practice exercise and a recap: certify the batch that arrives, not the one that left.

What you will be able to do

• Explain when samples may be taken in a third country
• Plan a study that shows third-country samples represent the batch
• Apply the conditions for batches made from one bulk

Why it matters

Sampling before shipment saves weeks only if data prove the samples represent the batch that arrives in the EU.

Practice: Practice: Sampling in a third country · 3 questions

Opens in December 2019, when EMA reported trace NDMA in some metformin medicines outside the EU, and asks what JKL Pharma Europe's QP must know about where MET500's metformin comes from. Reads point 1.7: twenty-one things the QP must ensure are secured, which may be delegated if she has ongoing assurance the reliance is well founded. Covers the first ten: GMP at every site, a documented supply chain, preferably as a diagram, audits with reports available to the QP, sites and activities matching the marketing authorisation, and active substances, excipients and TSE status under control. Shows part of JKL's supply chain record for MET500, from the metformin maker in India to Mumbai, Dublin and Frankfurt, and a contract steriliser on the diagram. Covers a Paris tablet maker using an active substance from Hong Kong, how JKL divides the checks, good practice, a common mistake and a recap.

What you will be able to do

• Map a batch's supply chain back to its active substance site
• Check that sites and materials match the marketing authorisation
• Explain when the QP may delegate checks and still rely on them

Why it matters

A QP who knows the supply chain can act within hours when a problem emerges; one who does not can only start searching.

Practice: Practice: What the QP must secure (1) · 3 questions

Starts on a Friday with MET500 batch 2452: every result in specification, but a new blister foil introduced by change, an open investigation into a dissolution trend, a complaint about a broken tablet and EU safety features to confirm. Takes the last eleven points in order: point 1.7.11 on complete, endorsed records and in-process checks, and point 1.7.12 on processes in a validated state and trained staff. Then results meeting the authorisation, stability supporting the shelf life, changes assessed, investigations sufficient, complaints that do not negate certification, agreements, self-inspection and shipping arrangements. Covers safety features affixed for the EU market, as the falsified pens case showed. Looks at ceftriaxone batch 5112 on a different day and an importer in Frankfurt. Shows JKL's review form with a findings box next to every point, good practice, a practice exercise and a recap: a tick records a belief, a finding records a check.

What you will be able to do

• Check records, validation and stability before certifying a batch
• Assess open changes, investigations and complaints before release
• Confirm that EU pack safety features are in place

Why it matters

Results in specification are not enough to certify; these checks catch what surrounds the batch.

Practice: Practice: What the QP must secure (2) · 3 questions

Opens with an audit report on the QP's desk: JKL contracted an audit firm to audit the metformin active substance maker in India, and the QP must rely on it. Explains Article 46, which lets the holder verify GMP through an entity acting under contract, while responsibility stays with the holder. Reads section 2 of Annex 16 and point 2.1, linking reliance on third-party audits to Chapter 7 on outsourced activities: a written contract, a defined scope and a qualified auditor, assessed and approved in writing by the QP. Shows JKL's audit scope, including the maker's nitrosamine risk assessment, and a shared audit of a Hong Kong active substance maker. Then unexpected deviations: when a QP may consider certifying, JKL's assessment for batch 2471, and why a third repeat triggers a review for a variation. Ends with good practice, the common mistake, a practice exercise and a recap.

What you will be able to do

• Assess whether a third-party audit report can be relied on
• Decide whether a batch with an unexpected deviation may be certified
• Recognise when a recurring deviation needs a variation instead

Why it matters

Reliance on others' audits and on deviation assessments is allowed only with evidence; this shows what that evidence is.

Practice: Practice: Third-party audits and unexpected deviations · 3 questions

Opens with a built near miss at JKL's Dublin warehouse, where an operator tries to pick uncertified ceftriaxone batch 5118 for an urgent hospital order and the warehouse system refuses. Reads point 4.1: release only after QP certification, with batches kept at the manufacturing site or shipped under quarantine to an approved site. Covers JKL's validated electronic safeguard and the QP's release notice recording her name and the time. Follows step 3 of batch release and shows an entry from JKL's electronic QP register, available for at least five years, with control reports travelling with the batch. Explains batch certificates under Appendix II, with the certificate for MET500 batch 2431-DE to Germany, and repackaged parallel imports certified by their own QP at a Paris distributor. Ends with good practice, a mistake urgency invites and a recap: urgency changes the priority, not the rule.

What you will be able to do

• Keep uncertified batches in quarantine with working safeguards
• Record each certification in a QP register that meets Annex 16
• Issue a batch certificate in line with Appendix II

Why it matters

An urgent order is when a batch is most likely to slip out uncertified; working safeguards stop it.

Practice: Practice: Release, the register and certificates · 3 questions

Follows MET500 batch 2480, a built example, through every stage. Stage 1 comes before the batch exists: the MIA, the marketing authorisation naming JKL Pharma Europe for release, a QP permanently available with a deputy, technical agreements, current audits and an up-to-date supply chain diagram. Then manufacture in Mumbai, quarantine transport, receipt and EU testing in Dublin, still sampled after arrival because the Mumbai sampling study is not complete. Shows the QP's review with findings, the nitrosamine risk assessment already held from the earlier audit, certification, the register and the control report, and the Frankfurt confirmation German packs would need. Covers what continues after release. Gives a readiness checklist for your own role, explains the final exam with one retake, and closes with the course recap in three words: the role, the process and the decision.

What you will be able to do

• Trace the evidence needed at each stage of an imported batch
• Prepare the foundations a QP needs before any batch exists
• Use a readiness checklist to test your own QP arrangements

Why it matters

Most of a QP's real work happens before the batch exists; seeing all stages together shows where to start.

Practice: Practice: Putting it together · 3 questions